Histopathology değerlendirme

GLP Compliance and Scientific Reporting in Histopathological Evaluation

The ultimate goal of preclinical toxicity and safety pharmacology studies is to identify, characterize, and quantify the potential adverse effects of a test substance on biological systems. The culmination of this process is the histopathology evaluation phase, in which all in vivo observations, clinical pathology data, organ weights, and macroscopic necropsy findings obtained throughout the study are integrated with microscopic tissue changes. This stage requires not only the identification of lesions but also the interpretation of their incidence, severity, and dose-response relationship with the test substance within a statistically significant framework. Nano-Tox Laboratory Services: Our Pathology Testing Unit conducts this complex and highly specialized evaluation process in accordance with Good Laboratory Practice (GLP) principles, using internationally accepted terminology and criteria.

Microscopic Examination by Board-Certified Specialists

The quality of a histopathological evaluation is directly related to the experience, area of expertise, and mastery of regulatory authority expectations of the pathologist performing it. The veterinary pathologists at Nano-Tox are board-certified by internationally recognized organizations such as the American College of Veterinary Pathologists (ACVP) or the European College of Veterinary Pathologists (ECVP). This team of experts possesses extensive toxicopathology experience in both rodent and non-rodent species and performs systematic microscopic examination of all tissue and organ lists defined in OECD test guidelines (e.g., 408, 409, 451, 453).

The evaluation process begins with a preliminary meeting with the study director. The pathologist receives a comprehensive briefing on the study design, dose groups, pharmacological properties of the test substance, and clinical observations. Microscopic examination is conducted using a blinded method whenever possible—that is, the pathologist scores the lesions without knowing which dose group is being examined. This approach minimizes observer bias, thereby enhancing the objectivity and scientific validity of the data.

Standardized Lesion Scoring and Terminology

To ensure that the histopathological findings are accepted by regulatory authorities and are comparable across different studies, it is essential that lesions be recorded using a standardized terminology and scoring system. At the Nano-Tox Pathology Testing Unit, guidelines published by the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) are used as a reference. For each finding, the nature, location, distribution, and severity of the lesion (typically on a semiquantitative scale of 1–5) are systematically graded. This standardization ensures that the study report can be directly integrated into international regulatory submissions (e.g., Common Technical Document – CTD Module 4).

Peer Review and Data Integrity

GLP principles require independent quality assurance and peer review processes to confirm the reliability of critical data.

At Nano-Tox laboratories, every histopathology evaluation completed by the primary pathologist responsible for the study undergoes a systematic peer review process conducted by an independent, board-certified second pathologist. During this process, a specific percentage of tissue sections—particularly those from target organs—are re-examined; diagnoses, scores, and terminology consistency are verified. The scope and outcome of the peer review process are clearly documented in the final pathology report. This practice not only maximizes data integrity but also provides proactive assurance against potential inquiries the sponsor may face during regulatory inspections.

Comprehensive Pathology Report and Integrated Interpretation

The final output of the histopathology evaluation process is a comprehensive report that summarizes, interprets, and integrates all pathology findings from the study. The pathology report prepared by Nano-Tox is not limited to tables of lesion incidence and severity. The report includes a narrative interpretation section detailing correlations between macroscopic observations, organ weight changes, and clinical pathology data and the microscopic findings. The relationship between the observed findings and the test substance (differential diagnosis from spontaneous background pathology), the dose-response relationship, and, if applicable, the reversibility profile are discussed. This comprehensive approach provides the sponsor’s study director and toxicology team with a clear, defensible, and regulatory-ready data package regarding the test substance’s safety profile.

At Nano-Tox Laboratory Services, we conduct the histopathology evaluation phase of your preclinical studies with the highest standards of scientific rigor and regulatory compliance. If you would like a trusted partner to manage the pathology data for your study, please contact our expert team to learn more about our Pathology Testing Unit.